Everand Logo

Welcome to Everand!

  • STAT

    How the drug industry keeps winning in Washington

    An insider's guide to the politics and policy of health care.
    by Nicholas Florko Jul 16, 2019 4 minutes

    D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

    How the drug industry keeps winning

    What if I told you the Sen. Thom Tillis campaign account was graced with nearly $20,000 in personal donations from drug industry CEOs and other top industry brass on Valentine’s Day? You’d think it was some cheesy made-for-TV movie about D.C.’s power elite, right? Well, it’s not: It’s just one of the many salacious details Lev and I dug up while reporting a big new story about how, despite all the inflammatory rhetoric, the drug industry

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
    Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
    Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

    Related Books & Audiobooks